Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer

Advanced endometrial cancer: New medical treatment options on the horizon

“…In addition, in most studies the results are negative. 6 Traditionally, the selection of adjuvant treatment in EC is based on stage, histological subtype, histological grade of differentiation, and a few histopathological prognostic factors such as lymphovascular space invasion. However, histopathological diagnostics have shortcomings, and the interrater reliability among pathologists is as low as 30%.…”

“…3,9 The POLEmut subtype constitutes 5%-10% of EC cases. 6 These tumors are characterized by a very high mutation frequency, high tumor infiltrating lymphocytes, and low copy number alterations.…”

“…Numerous studies have explored whether chemotherapy results in prolonged survival, but many have included both high‐ and low‐risk patients often combined with radiotherapy in one or both arms, which makes it difficult to interpret the results. In addition, in most studies the results are negative 6 …”

“…Their profile is similar to POLEmut tumors, with a high mutational burden, extensive infiltration of lymphocytes, and low copy number alterations, but mutations are present in different genes and the prognosis is intermediate. Copy number low is the most predominant subtype observed and constitutes around 40% of EC cases with a low mutational burden and frequent expression of hormone‐receptors 6 . This group is heterogeneous, and the prognosis is variable.…”

“…This group is heterogeneous, and the prognosis is variable. Copy number high is the fourth subtype, observed in 25%–30% of EC cases 6 . This subtype, which includes serous EC, has the worst prognosis and is associated with mutations in the TP53 gene in >90% of cases.…”